New drug combo aims to fight rare thymus cancers after first treatment fails
NCT ID NCT06838910
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two drugs—tislelizumab (an immunotherapy) and anlotinib (a targeted therapy)—as a second-line treatment for people with thymoma or thymic carcinoma whose cancer has progressed after initial chemotherapy. The study will enroll 20 participants at a single center in China. The main goal is to see how many patients experience tumor shrinkage or disappearance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab (an immunotherapy drug) combined with anlotinib (a targeted therapy drug)
- What this could lead to
- If successful, this combination could offer a new second-line treatment option for people with thymoma or thymic carcinoma whose cancer has progressed after initial therapy.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The combination may cause side effects or fail to shrink tumors in many patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter radiation after thymic tumor surgery may cut side effects
- Fewer radiation sessions may be just as effective for thymic tumors after surgery
- Talking therapy shows promise for MG patients with depression in tiny pilot study
- Immune cells engineered to hunt thymus cancer show promise in early trial
- Immunotherapy drug nivolumab tested for rare thymus cancers
- New study aims to uncover hidden clues in myasthenia gravis